Cargando...
Economic Outcomes of Isavuconazole to Prevent Invasive Fungal Infection in Immunocompromised Adults: Initial Experience at an Academic Medical Center
BACKGROUND: Isavuconazole (ISA) is a once-daily, extended-spectrum triazole approved for treatment of invasive aspergillosis and mucormycosis. The pharmacokinetic profile, daily dosing, lack of therapeutic drug monitoring (TDM) and reduced cost make ISA a promising option for use as prophylaxis for...
Gardado en:
| Publicado en: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5630875/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1264 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|